Mecamylamine

Generic Name: Mecamylamine

Brand Names: Inversine, Vecamyl

Drug Type: Small Molecule

Chemical Formula: C_₁₁H_₂₁N

CAS Number: 60-40-2

Background: A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.

Indication: For the treatment of moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension

Associated Conditions: Severe Hypertension, Moderate Hypertension, Uncomplicated Malignant hypertension

Clinical Trials

Attentional Mechanisms in SCD

Early Phase 1

Not yet recruiting

Conditions: Subjective Cognitive Decline

Interventions: Drug: Mecamylamine Challenge
Other: Placebo Comparator Challenge

First Posted Date: 2023-08-21

Last Posted Date: 2025-05-13

Lead Sponsor: Vanderbilt University Medical Center

Target Recruit Count: 80

Registration Number: NCT06002477

Locations: 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

Cholinergic Mechanisms of Attention in Aging

Early Phase 1

Recruiting

Conditions: Subjective Cognitive Decline

Interventions: Drug: Mecamylamine Challenge
Other: Placebo Comparator Challenge

First Posted Date: 2021-02-16

Last Posted Date: 2024-08-26

Lead Sponsor: Vanderbilt University Medical Center

Target Recruit Count: 80

Registration Number: NCT04756232

Locations: 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

Mecamylamine for Autonomic Dysreflexia Prophylaxis

Phase 4

Conditions: Spinal Cord Injuries

Interventions: Drug: Mecamylamine Oral Tablet

First Posted Date: 2019-04-16

Last Posted Date: 2019-10-07

Lead Sponsor: Wayne State University

Target Recruit Count: 5

Registration Number: NCT03914677

Locations: 🇺🇸
Wayne State University, Detroit, Michigan, United States

Mental Ability Challenge Study in Adults With and Without HIV

Completed

Conditions: Memory Impairment
HIV-Associated Cognitive Motor Complex
Aging, Premature
Cognitive Impairment
HIV-1-infection

Interventions: Drug: Scopolamine Injectable Product
Drug: Mecamylamine Pill

First Posted Date: 2017-08-09

Last Posted Date: 2019-02-25

Lead Sponsor: Vanderbilt University Medical Center

Target Recruit Count: 22

Registration Number: NCT03244488

Locations: 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

Nicotinic Modulation of the Default Network

Not Applicable

Completed

Conditions: Magnetic Resonance Imaging
Cognition
Nicotine
Mecamylamine

Interventions: Drug: Placebo
Drug: Nicotine
Drug: Mecamylamine

First Posted Date: 2010-10-19

Last Posted Date: 2019-08-19

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 21

Registration Number: NCT01223404

Locations: 🇺🇸
National Institute on Drug Abuse, Intramural Research Program, Baltimore, Maryland, United States
🇺🇸
Maryland Psychiatric Research Center, Baltimore, Maryland, United States

Placebo-Controlled Pilot Trial of Mecamylamine for Treatment of Autism Spectrum Disorders

Phase 1

Completed

Conditions: Pervasive Developmental Disorder
Autistic Disorder

Interventions: Drug: placebo
Drug: mecamylamine

First Posted Date: 2008-10-16

Last Posted Date: 2017-01-13

Lead Sponsor: Ohio State University

Target Recruit Count: 20

Registration Number: NCT00773812

Locations: 🇺🇸
Nisonger Center, Columbus, Ohio, United States

Flexible Dose Titration Add-on Study to Treat Major Depressive Disorder

Phase 2

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Mecamylamine

First Posted Date: 2008-01-15

Last Posted Date: 2008-01-15

Lead Sponsor: Targacept Inc.

Target Recruit Count: 450

Registration Number: NCT00593879

Mecamylamine for the Treatment of Patients With Depression and Alcohol Dependence

Phase 3

Completed

Conditions: Alcohol Dependence
Depression

Interventions: Drug: Mecamylamine
Drug: Placebo

First Posted Date: 2007-11-26

Last Posted Date: 2016-04-18

Lead Sponsor: Yale University

Target Recruit Count: 21

Registration Number: NCT00563797

Locations: 🇺🇸
VA Connecticut Healthcare System, West Haven, Connecticut, United States

Topical Ocular Mecamylamine in Diabetic Macular Edema (DME)

Phase 2

Completed

Conditions: Diabetic Macular Edema

First Posted Date: 2007-09-28

Last Posted Date: 2008-04-08

Lead Sponsor: CoMentis

Registration Number: NCT00536692

Locations: 🇺🇸
Ophthalmic Consultants of Boston, Boston, Massachusetts, United States
🇺🇸
Johns Hopkins School of Medicine / Wilmer Eye Institute, Baltimore, Maryland, United States
🇺🇸
East Bay Retina Consultants, Inc., Oakland, California, United States

Study of the Effects of Mecamylamine and Varenicline in Schizophrenia

Not Applicable

Completed

Conditions: Cognition in Schizophrenia

Interventions: Drug: Placebo
Drug: Mecamylamine
Drug: Varenicline

First Posted Date: 2007-04-04

Last Posted Date: 2017-03-28

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 89

Registration Number: NCT00455650

Locations: 🇺🇸
Freedom Trail Clinic, Massachusetts General Hospital, Boston, Massachusetts, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy